AI-generated analysis. Always verify with the original filing.
Bio-Rad Laboratories, Inc. announced Q4 and full-year 2025 financial results with Q4 revenue of $693.2 million (up 3.9% YoY) and full-year revenue of $2,583.2 million (up 0.7% YoY), alongside non-GAAP operating margins and 2026 guidance for 0.5-1.5% currency neutral revenue growth. Results reflect Clinical Diagnostics growth offset by Life Science declines due to funding constraints, with significant Sartorius AG investment gains driving GAAP net income.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition On February 12, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter e
, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference. ITEM 7.01 Regulation FD
Financial Statements and Exhibits Exhibit Number Description 99.1 Press release of Bio-Rad Laboratories, Inc. dated February 1 2 , 20 26 99.2 Supplemental Earni
| Metric | Value | Basis |
|---|---|---|
| Revenue | $693.20 | |
| Gross margin | 49.8% | GAAP |
| Income (loss) from operations | $-118.90 | GAAP |
| Net income (loss) | $720.00 | GAAP |
| Net income (loss) per diluted share | $26.65 | GAAP |
| Gross margin | 52.5% | Non-GAAP |
| Income from operations | $83.00 | Non-GAAP |
| Net income | $67.70 | Non-GAAP |
| Net income per diluted share | $2.51 | Non-GAAP |
| Revenue | $2.6K | |
| Gross margin | 51.9% | GAAP |
| Income from operations | $47.20 | GAAP |
| Net income (loss) | $759.90 | GAAP |
| Net income (loss) per diluted share | $27.85 | GAAP |
| Gross margin | 53.3% | Non-GAAP |
| Income from operations | $311.60 | Non-GAAP |
| Net income | $270.50 | Non-GAAP |
| Net income per diluted share | $9.92 | Non-GAAP |